OrthoPediatrics (KIDS)
(Delayed Data from NSDQ)
$28.74 USD
-0.47 (-1.61%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $28.69 -0.05 (-0.17%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
KIDS 28.74 -0.47(-1.61%)
Will KIDS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for KIDS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KIDS
BiomX Stock Gains From Favorable Study Data Presentation on BX004
VERO Stock Likely to Get Support From New Regulatory Nod in Australia
KIDS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Abbott Stock Hurt by Macroeconomic Issues & FX Headwind
QGEN Stock Likely to Gain From Newly Launched Assays for QIAcuity
BSX Gets FDA Nod on INGEVITY+ Pacing Lead in the LBBA: Stock to Gain?
Other News for KIDS
Needham medtech & diagnostics analyst holds analyst/industry conference call
Needham medtech & diagnostics analyst holds analyst/industry conference call
Buy Rating Reaffirmed for OrthoPediatrics on Robust Growth Strategy and Strong Financials
OrthoPediatrics price target raised by $4 at Truist, here's why
OrthoPediatrics Corp. Announces Launch of Enabling Technologies Division